Patient characteristics, spondyloarthritis (SpA) features, treatment and outcome in vedolizumab-treated patients with inflammatory bowel disease (IBD) presenting with arthritis or sacroiliitis
| Gender | Age | HLA-B27 | Smoker | Concomitant medication | IBD | Response of gut inflammation | Prior diagnosis of SpA | TTF (days) | SpA feature | Therapy | Outcome of SpA feature at 6 months | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 50 | Neg | No | Mesalazine | CD | Good HBI 0 at week 14 | No | 60 | Sacroiliitis | Single IA SIJ, chronic (Cox2 selective) NSAID | Clinical remission and imaging improvement |
| 2 | F | 28 | Neg | No | AZA | UC | Good Mayo 0 at week 10 | No | 58 | Arthritis | Single IA | Clinical and imaging remission |
| 3 | M | 30 | Neg | No | AZA | CD | Good HBI 0 at week 28 | Yes (axial disease) | 14 | Sacroiliitis | Chronic (Cox2 selective) NSAID | Active disease |
| 4 | F | 47 | Neg | Yes | Mesalazine | CD | Good HBI 2 at week 20+HBI 1 at week 32 | No | 114 | Sacroiliitis | Single IA SIJ | Clinical remission |
| 5 | F | 26 | Neg | No | None | UC | Poor Mayo 3 at week 10 | No | 73 | Arthritis | OCS | Clinical remission |
AZA, azathioprine 100 mg; CD, Crohn's disease; F, female; HBI, Harvey-Bradshaw Index; IA, intra-articular infiltration; M, male; NSAID, non-steroidal anti-inflammatory drugs; OCS, oral corticosteroids; SIJ, sacroiliac joints; TTF, time to flare; UC, ulcerative colitis.